BioLamina's Avatar

BioLamina

@biolaminaab.bsky.social

#StemCells and beyond! The world’s only manufacturer of full-length human recombinant laminins, Biolaminin®. We support scientists in advancing reproducible discoveries—from bench to clinic.

38 Followers  |  166 Following  |  7 Posts  |  Joined: 27.09.2024
Posts Following

Posts by BioLamina (@biolaminaab.bsky.social)

Post image

A research team discovered a beneficial subtype of macrophages that are drastically exhausted in an atopic dermatitis mouse model and restored these cells by reinforcing a natural cue from fibroblasts: full-length laminin proteins.

Read more in Cell. Mol. Life Sci: link.springer.com/article/10.1...

22.01.2025 17:04 — 👍 0    🔁 0    💬 0    📌 0
Preview
Arrayed CRISPR libraries for the genome-wide activation, deletion and silencing of human protein-coding genes - Nature Biomedical Engineering Arrayed CRISPR libraries with each plasmid encoding an array of four non-overlapping single-guide RNAs allow for the efficient genome-wide ablation, activation and epigenetic silencing of human protei...

Have you already read about the ALPA #cloning system?

Arrayed #CRISPR libraries w/ quadruple-gRNAs enhance gene perturbation efficiency and enable previously inaccessible screens.

#Gene knockout and ablation efficiencies were studied in #iPSCs and #kidney organoids.

www.nature.com/articles/s41...

13.12.2024 12:55 — 👍 1    🔁 0    💬 0    📌 0
Preview
Effect of extracellular matrix proteins on the differentiation of human pluripotent stem cells into mesenchymal stem cells The transplantation of human mesenchymal stem cells (hMSCs), such as bone marrow stem cells (BMSCs) and adipose-derived stem cells (ADSCs), has shown beneficial effects in protecting transplanted tiss...

#MSCs from #StemCells and osteoblastic differentiation—challenging!

At least the matrix of choice is easy: after extensive comparisons, Tian et al. conclude #LN521 performs the best. Consistently high
- proliferation
- MSC marker expression
- osteogenic differentiation

pubs.rsc.org/en/content/a...

02.12.2024 12:40 — 👍 0    🔁 0    💬 0    📌 0
Preview
BioLamina on LinkedIn: Gain of 1q confers an MDM4-driven growth advantage to undifferentiated and… Cells with recurrent genomic aberrations, such as 1q gain, are prevalent in hPSC lines globally. This aberration has been linked to culture conditions. DNA…

Hi! We are a biotech company producing laminin proteins for stem cell biologists and beyond. We would participate in the feed by sharing engaging summaries for recent publications in stem cell research, incl. tissue modeling and cell therapy.
E.g. www.linkedin.com/posts/biolam... Please add us :)

01.12.2024 06:30 — 👍 0    🔁 0    💬 0    📌 0
Redirecting


Why not learn about #laminins and #cancer for a few minutes?

These basement membrane proteins influence how #cells sense ECM stiffness, affecting whether malignant cells breach barriers—a key step in #metastasis.

Read more on the recent review: www.sciencedirect.com/science/arti...

29.11.2024 18:51 — 👍 1    🔁 0    💬 0    📌 0
Preview
Gain of 1q confers an MDM4-driven growth advantage to undifferentiated and differentiating hESC while altering their differentiation capacity - Cell Death & Disease Cell Death & Disease - Gain of 1q confers an MDM4-driven growth advantage to undifferentiated and differentiating hESC while altering their differentiation capacity

How do you keep your stem cells genomically stable?

1q gain is a frequent aberration and is linked to culture conditions.

N. Krivec et al. showed that 1q-gained hPSCs can also take over during differentiation resulting in more immature cells.

Read more: doi.org/10.1038/s414...

#StemCell

25.11.2024 08:54 — 👍 0    🔁 0    💬 0    📌 0
BioLamina will have a webinar on December 10 (4–5 pm CET) on "Treating Blindness with Stem Cell Therapies". The speakers are Laura Koivusalo, PhD, CEO and Founder, StemSight Oy, Finland; 
Anders Kvanta, PhD, Ophthalmologist, Vitreoretinal Surgeon, and Retinal Disease Researcher, St Erik Eye Hospital, Sweden; 
Fredrik Lanner, PhD, Assistant Professor, Stem Cell Biologist, Karolinska Institute, Sweden; Stijn Heessen, PhD, Chief Operations Officer, Alder Therapeutics AB, Sweden; Kristian Tryggvason, PhD, MBA, CEO and Founder, Alder Therapeutics AB, Sweden, and Susanna Teppo, PhD, Scientific Marketing Specialist, BioLamina AB, Sweden.

Welcome!

BioLamina will have a webinar on December 10 (4–5 pm CET) on "Treating Blindness with Stem Cell Therapies". The speakers are Laura Koivusalo, PhD, CEO and Founder, StemSight Oy, Finland; Anders Kvanta, PhD, Ophthalmologist, Vitreoretinal Surgeon, and Retinal Disease Researcher, St Erik Eye Hospital, Sweden; Fredrik Lanner, PhD, Assistant Professor, Stem Cell Biologist, Karolinska Institute, Sweden; Stijn Heessen, PhD, Chief Operations Officer, Alder Therapeutics AB, Sweden; Kristian Tryggvason, PhD, MBA, CEO and Founder, Alder Therapeutics AB, Sweden, and Susanna Teppo, PhD, Scientific Marketing Specialist, BioLamina AB, Sweden. Welcome!

We're looking forward to sharing, learning, and working together here!
We'd like to invite you to our webinar. Experts will discuss the latest advancements in #PSC therapy, sharing insights into how it is already transforming vision restoration, and what lies ahead ⏬
tinyurl.com/ajrh3k64

#stemcell

21.11.2024 13:36 — 👍 1    🔁 0    💬 0    📌 0